European Registry on Helicobacter pylori Management : Effectiveness of First and Second-Line Treatment in Spain
Caldas, María (Instituto de Investigación Hospital Universitario de la Princesa)
Pérez-Aisa, Ángeles (Agencia Sanitaria Costa del Sol (Andalusia))
Castro-Fernández, Manuel (Hospital Universitario Virgen de Valme (Sevilla, Andalusia))
Bujanda, Luis (Biodonostia Osasun Ikerketako Institutura (País Basc))
Lucendo, Alfredo J. (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas)
Rodrigo-Sáez, Luis (Hospital Universitario Central de Asturias)
Huguet, José María (Hospital General Universitario de Valencia)
Pérez-Lasala, Jorge (Hospital Universitario HM Sanchinarro (Madrid))
Molina-Infante, Javier (Hospital San Pedro de Alcántara)
Barrio, Jesús (Hospital Universitario Río Hortega (Valladolid))
Fernández-Salazar, Luis (Hospital Clínico Universitario de Valladolid)
Lanas, Ángel (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza)
Perona, Mónica (Gastroenterology Unit, Hospital Quirón Marbella)
Domínguez-Cajal, Manuel (Hospital General Universitario San Jorge (Osca, Aragó))
Ortuño, Juan (Hospital Universitari i Politècnic La Fe (València))
Gómez-Rodríguez, Blas José (Hospital Universitario Virgen Macarena (Sevilla, Andalusia))
Almela, Pedro (Consorci Hospitalari Provincial de Castelló)
Botargués, Josep María (Hospital Universitari de Bellvitge)
Núñez, Óscar (Digestive Service, Hospital Universitario Sanitas La Moraleja)
Modolell, Inés (Consorci Sanitari Hospital de Terrassa)
Gómez, Judith (Digestive Service, Complejo Asistencial Universitario de Burgos)
Ruiz-Zorrilla, Rafael (Hospital Sierrallana)
De la Coba, Cristóbal (Hospital Universitario de Cabueñes (Gijón))
Huerta, Alain (Hospital de Galdakao (Usansolo, Biscaia))
Iyo, Eduardo (Hospital Comarcal de Inca)
Pozzati, Liliana (Digestive Service, Hospital de Mérida (Extremadura))
Antón, Rosario (Hospital Clínic Universitari (València))
Barenys, Mercé (Hospital de Viladecans (Catalunya))
Angueira, Teresa (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas)
Fernández-Bermejo, Miguel (Digestive Service, Clínica San Francisco (Extremadura))
Campillo, Ana (Hospital Universitario Reina Sofía (Córdoba, Espanya))
Alcedo, Javier (Hospital de Barbastro)
Pajares-Villaroya, Ramón (Hospital Universitario Infanta Sofía (San Sebastián de los Reyes))
Mego Silva, Marianela (Hospital Universitari General de Catalunya)
Bermejo, Fernando (Instituto de Investigación Sanitaria del Hospital Universitario La Paz)
Dominguez-Jiménez, José Luis (Hospital Alto del Guadalquivir)
Titó, Llúcia (Hospital de Mataró. Consorci Sanitari del Maresme)
Fernández, Nuria (Agencia Sanitaria Costa del Sol (Andalusia))
Pabón-Carrasco, Manuel (Universidad de Sevilla)
Cosme, Ángel (Biodonostia Osasun Ikerketako Institutura (País Basc))
Mata-Romero, Pilar (Hospital San Pedro de Alcántara)
Alcaide, Noelia (Hospital Clínico Universitario de Valladolid)
Ariño, Inés (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza)
Di Maira, Tommaso (Hospital Universitari i Politècnic La Fe (València))
Garre, Ana (Instituto de Investigación Hospital Universitario de la Princesa)
Puig, Ignasi (Universitat de Vic)
Nyssen, Olga P. (Instituto de Investigación Hospital Universitario de la Princesa)
Megraud, Francis (Université de Bordeaux)
O'Morain, Colm (Department of Clinical Medicine, Trinity College Dublin)
P. Gisbert, Javier (Instituto de Investigación Hospital Universitario de la Princesa)
Universitat Autònoma de Barcelona

Data:	2020
Resum:	The management of Helicobacter pylori infection has to rely on previous local effectiveness due to the geographical variability of antibiotic resistance. The aim of this study was to evaluate the effectiveness of first and second-line H. pylori treatment in Spain, where the empirical prescription is recommended. A multicentre prospective non-interventional registry of the clinical practice of European gastroenterologists concerning H. pylori infection (Hp-EuReg) was developed, including patients from 2013 until June 2019. Effectiveness was evaluated descriptively and through a multivariate analysis concerning age, gender, presence of ulcer, proton-pump inhibitor (PPI) dose, therapy duration and compliance. Overall, 53 Spanish hospitals were included, and 10,267 patients received a first-line therapy. The best results were obtained with the 10-day bismuth single-capsule therapy (95% cure rate by intention-to-treat) and with both the 14-day bismuth-clarithromycin quadruple (PPI-bismuth-clarithromycin-amoxicillin, 91%) and the 14-day non-bismuth quadruple concomitant (PPI-clarithromycin-amoxicillin-metronidazole, 92%) therapies. Second-line therapies were prescribed to 2448 patients, with most-effective therapies being the triple quinolone (PPI-amoxicillin-levofloxacin/moxifloxacin) and the bismuth-levofloxacin quadruple schemes (PPI-bismuth-levofloxacin-amoxicillin) prescribed for 14 days (92%, 89% and 90% effectiveness, respectively), and the bismuth single-capsule (10 days, 88. 5%). Compliance, longer duration and higher acid inhibition were associated with higher effectiveness. "Optimized" H. pylori therapies achieve over 90% success in Spain.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Helicobacter pylori ; Treatment ; First-line ; Second-line ; Spain
Publicat a:	Antibiotics, Vol. 10 (december 2020) , ISSN 2079-6382

DOI: 10.3390/antibiotics10010013
PMID: 33375717

15 p, 909.6 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats